Log in
menu
RESOURCES
Guides
API
FAQ
Recent Changes
Report Issue
ABOUT
About Wikirate
Community
Data
Impact
All Categories
--------------
Companies
Metrics
Sources
Topics
Data Sets
Projects
Research Groups
Company Groups
search
arrow_back_ios
Companies
Metrics
Sources
Topics
Data Sets
Projects
Research Groups
Company Groups
arrow_forward_ios
Home
Answers
World Benchmarking Alliance+NAT.B01.EB Assessment of Impacts on Nature Upstream Value Chain+Astellas Pharma+2022
attribution
history
edit
build
Question:
Does the company assess its impacts on nature, including biodiversity, in the upstream activities of its value chain?
Answer:
No
WikiRate ID:
18333224
Metric Designer:
World Benchmarking Alliance
Metric Title:
NAT.B01.EB Assessment of Impacts on Nature Upstream Value Chain
Company:
Astellas Pharma
Year:
2022
Status:
Unverified - Added by Steward
Details
Years
1
calculations
4
Contributions
updated
about 2 months ago by
World Benchmarking Alliance
Review
Flag!
Source
history
edit
build
Nature Benchmark 2023/2022
Answers
0
more_horiz
file_download
Download
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
edit
Edit
build
Advanced
Comments
history
edit
build
No evidence that the company assesses its impacts on nature, including biodiversity, in the upstream activities of its value chain could be found in the public domain.